drug_type
RELEVANT_DRUG
intervention_type
Cellular immunotherapy
drug_description
Adoptive cellular immunotherapy using virus-specific CTL lines engineered with glucocorticoid receptor (GR/NR3C1) knockout to resist steroid-mediated suppression/apoptosis; HLA-restricted recognition of adenovirus, BK virus, CMV, JC virus, or SARS-CoV-2 antigens on infected cells, leading to perforin/granzyme-mediated killing and antiviral cytokine release; administered intravenously with possible repeat dosing.
nci_thesaurus_concept_id
C131870
nci_thesaurus_definition
A population of cytotoxic T-lymphocytes (CTLs) specifically reactive to one or more pre-selected viruses, with potential antiviral activity. Upon infusion, after an allogeneic hematopoietic cell transplant (HCT) or in other immunodeficient states, these CTLs help reconstitute viral-specific CTL responses and kill virally infected cells, thereby inhibiting viral infection in immunocompromised patients.
drug_mesh_term
T-Lymphocytes, Cytotoxic
drug_category
TCR SELECTED T CELLS
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Adoptively transferred, virus-specific CTLs recognize viral peptides presented on HLA molecules via their native TCRs and eliminate infected cells through perforin/granzyme-mediated cytolysis and antiviral cytokine secretion. The cells are engineered with glucocorticoid receptor (NR3C1) knockout to resist steroid-induced suppression and apoptosis, improving persistence and antiviral activity in immunosuppressed patients.
drug_name
Virus-specific Cytotoxic T-lymphocytes
nct_id_drug_ref
NCT05101213